Format

Send to

Choose Destination
Cancer Lett. 2012 Dec 28;325(2):125-31. doi: 10.1016/j.canlet.2012.06.009. Epub 2012 Jun 28.

Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer.

Author information

1
UCL Institute of Liver and Digestive Health, Royal Free Campus, London, United Kingdom. m.waugh@ucl.ac.uk

Abstract

This article focuses on the emerging roles for phosphatidylinositol 4-phosphate and the phosphatidylinositol 4-kinases in cancer. Phosphatidylinositol 4-phosphate is a common substrate for both the phosphatidylinositol 3-kinase and phospholipase C pathways, and has been implicated in the membrane targeting of proteins such as Girdin/GIV and OSBP. Alterations to phosphatidylinositol 4-kinase expression levels can modulate MAP kinase and Akt signalling, and are important for chemoresistance, tumour angiogenesis and the suppression of apoptosis and metastases. Recent improvements in high-throughput screening assays, and the discoveries that some anti-viral molecules are isoform selective phosphatidylinositol 4-kinase inhibitors have advanced the drugability of these enzymes.

PMID:
22750097
DOI:
10.1016/j.canlet.2012.06.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center